Skip to main content

Table 3 Univariate and multivariate analysis of prognostic factor for overall survival

From: Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients

Variables

Univariate

Multivariate

HR (95% CI)

p value

HR (95% CI)

p value

Age

1.01 (0.99–1.03)

0.529

 

–

ECOG PS

 

0.375

 

–

 0

Reference

   

 1–2

1.39 (0.67–2.89)

   

Child-Pugh class

 

< 0.001

 

< 0.001

 A

Reference

 

Reference

 

 B

3.98 (2.29–6.92)

 

3.13 (1.73–5.67)

 

Etiology

 

0.819

 

–

 HBV

Reference

   

 Others

1.06 (0.64–1.75)

   

BCLC stage

 

0.021

 

0.860

 0

Reference

 

Reference

 

 A

1.71 (1.08–2.69)

 

0.94 (0.49–1.80)

 

Tumor size

1.29 (1.04–1.61)

0.021

1.26 (0.99–1.59)

0.059

Alpha-fetoprotein

 

0.089

 

0.341

 ≤ 20 ng/mL

Reference

 

Reference

 

 >  20 ng/mL

1.47 (0.94–2.30)

 

1.25 (0.79–1.98)

 

Number of prior treatment sessions

1.04 (0.98–1.10)

0.209

 

–

BED

0.97 (0.95–0.98)

< 0.001

0.98 (0.96–1.00)

0.014

CR at 3 months

 

0.236

 

–

 Yes

Reference

   

 No

1.33 (0.83–2.14)

   

anyCRa

 

0.062

 

0.094

 Yes

Reference

 

Reference

 

 No

2.38 (0.96–5.93)

 

2.23 (0.87–5.68)

 
  1. Abbreviations: HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, BED biologically effective dose, CR complete response
  2. aAchievement of complete response according to the mRECIST criteria at the time point of the best response during the entire follow-up period